Cellebrite DI (CLBT) EBITDA Margin (2020 - 2025)

Cellebrite DI's EBITDA Margin history runs 6 years deep, the most recent figure standing at 16.15% for Q4 2025.

• On a quarterly basis, EBITDA Margin rose 173.0% year-over-year to 16.15% in Q4 2025; TTM through Dec 2025 was 13.98%, a 21.0% decrease from a year earlier, with the FY2025 full-year figure at 13.98%, down 1079.0% from the prior year.
• EBITDA Margin improved to 16.15% in Q4 2025 per CLBT's latest filing, from 15.07% in the prior quarter.
• Across five years, EBITDA Margin topped out at 24.7% in Q3 2023 and bottomed at 13.19% in Q4 2022.
• The 5-year median for EBITDA Margin is 10.86% (2025), against an average of 8.61%.
• Across the five-year window, EBITDA Margin tumbled 2284 bps in 2022 and soared 3766 bps in 2023, its largest moves.
• Year by year, EBITDA Margin stood at 6.34% in 2021, then plunged by 308 bps to 13.19% in 2022, then surged by 285 bps to 24.47% in 2023, then tumbled by 41 bps to 14.42% in 2024, then rose by 12 bps to 16.15% in 2025.
• Per Business Quant, the three latest CLBT EBITDA Margin figures stand at 16.15% (Q4 2025), 15.07% (Q3 2025), and 12.73% (Q2 2025).